AveXis, Inc. (AVXS) VP Sells $168,690.60 in Stock

AveXis, Inc. (NASDAQ:AVXS) VP Sukumar Nagendran sold 1,780 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $94.77, for a total value of $168,690.60. Following the sale, the vice president now owns 1,780 shares in the company, valued at approximately $168,690.60. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Sukumar Nagendran also recently made the following trade(s):

  • On Wednesday, November 1st, Sukumar Nagendran sold 1,780 shares of AveXis stock. The stock was sold at an average price of $101.26, for a total value of $180,242.80.
  • On Monday, October 2nd, Sukumar Nagendran sold 1,780 shares of AveXis stock. The stock was sold at an average price of $97.25, for a total value of $173,105.00.

AveXis, Inc. (AVXS) opened at $98.70 on Friday. AveXis, Inc. has a 1-year low of $44.68 and a 1-year high of $108.27.

AveXis (NASDAQ:AVXS) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($1.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.04). During the same quarter in the previous year, the business earned ($0.87) earnings per share. equities research analysts forecast that AveXis, Inc. will post -6.23 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the business. Strs Ohio acquired a new position in AveXis in the 3rd quarter valued at $116,000. Botty Investors LLC acquired a new position in AveXis in the 2nd quarter valued at $123,000. Ameritas Investment Partners Inc. grew its holdings in AveXis by 331.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,112 shares of the company’s stock valued at $174,000 after buying an additional 1,622 shares in the last quarter. Cubist Systematic Strategies LLC grew its holdings in AveXis by 688.6% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock valued at $175,000 after buying an additional 1,577 shares in the last quarter. Finally, Teacher Retirement System of Texas acquired a new position in AveXis in the 3rd quarter valued at $200,000. 92.88% of the stock is currently owned by hedge funds and other institutional investors.

A number of brokerages have recently issued reports on AVXS. ValuEngine cut AveXis from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Bank of America decreased their target price on AveXis from $115.00 to $112.00 and set a “buy” rating on the stock in a report on Friday, November 10th. Royal Bank Of Canada boosted their target price on AveXis from $92.00 to $97.00 and gave the stock a “sector perform” rating in a report on Friday, November 10th. Chardan Capital reissued a “buy” rating on shares of AveXis in a report on Thursday, November 2nd. Finally, Zacks Investment Research lowered AveXis from a “buy” rating to a “hold” rating in a report on Monday, October 30th. Three analysts have rated the stock with a sell rating, three have assigned a hold rating and thirteen have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $110.67.

COPYRIGHT VIOLATION WARNING: “AveXis, Inc. (AVXS) VP Sells $168,690.60 in Stock” was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://ledgergazette.com/2017/12/08/avexis-inc-avxs-vp-sells-168690-60-in-stock.html.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Insider Buying and Selling by Quarter for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply